Compare LBRDA & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRDA | TGTX |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | United States |
| Employees | 1900 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.5B |
| IPO Year | N/A | 2008 |
| Metric | LBRDA | TGTX |
|---|---|---|
| Price | $33.85 | $53.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $49.80 |
| AVG Volume (30 Days) | 209.5K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | N/A | $49.08 |
| Revenue Next Year | $109.28 | $26.69 |
| P/E Ratio | ★ $8.39 | $457.29 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.14 | $25.37 |
| 52 Week High | $65.40 | $59.30 |
| Indicator | LBRDA | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 51.91 |
| Support Level | $31.91 | $51.15 |
| Resistance Level | $34.90 | $58.34 |
| Average True Range (ATR) | 1.49 | 2.23 |
| MACD | 0.37 | -0.57 |
| Stochastic Oscillator | 100.00 | 36.41 |
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.